Recent Research Analysts’ Ratings Updates for Olema Pharmaceuticals (OLMA)

Olema Pharmaceuticals (NASDAQ: OLMA) recently received a number of ratings updates from brokerages and research firms:

• 11/21/2025 – Olema Pharmaceuticals had its price target raised by analysts at The Goldman Sachs Group, Inc. from $18.00 to $26.00. They now have a “buy” rating on the stock.
• 11/18/2025 – Olema Pharmaceuticals had its price target raised by analysts at Oppenheimer Holdings, Inc. from $22.00 to $45.00. They now have an “outperform” rating on the stock.
• 11/18/2025 – Olema Pharmaceuticals had its price target raised by analysts at HC Wainwright from $28.00 to $36.00. They now have a “buy” rating on the stock.
• 11/18/2025 – Olema Pharmaceuticals had its price target raised by analysts at JPMorgan Chase & Co. from $29.00 to $32.00. They now have an “overweight” rating on the stock.
• 10/20/2025 – Olema Pharmaceuticals had its “buy” rating reaffirmed by analysts at UBS Group AG.
• 10/20/2025 – Olema Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $28.00 price target on the stock.
• 10/8/2025 – Olema Pharmaceuticals had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 10/8/2025 – Olema Pharmaceuticals is now covered by analysts at Guggenheim. They set a “buy” rating and a $20.00 price target on the stock.

Insider Activity at Olema Pharmaceuticals

In other news, Director Cyrus Harmon sold 3,086 shares of the stock in a transaction dated Thursday, September 18th. The shares were sold at an average price of $8.32, for a total transaction of $25,675.52. Following the completion of the sale, the director owned 117,028 shares in the company, valued at approximately $973,672.96. This represents a 2.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 25,000 shares of company stock valued at $204,841 over the last three months. 16.36% of the stock is currently owned by corporate insiders.

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.